Minimal residual disease in chronic myeloid leukemia.
Löwenberg
Bob
B
Erasmus University Medical Center, Rotterdam, The Netherlands.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000097:blood; D003561:Cytarabine / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000097:blood*; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014158:Transcription, Genetic
D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D003561:Cytarabine; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl